ARK Invest's position in CDNA, updated every trading day. Data as of 2026-11-12.
| Fund | Shares | Value | Weight | Rank |
|---|---|---|---|---|
| ARKG | 900,295 | $71.9M | 3.64% | #12 |
| Trade day | Fund | Side | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-11-06 | ARKG | Sell | Trimmed | 113,168 | $8.9M |
| 2026-11-05 | ARKG | Sell | Trimmed | 63,092 | $4.8M |
| 2026-11-04 | ARKG | Sell | Trimmed | 12,996 | $1.1M |
| 2026-11-03 | ARKG | Sell | Trimmed | 31,538 | $2.8M |
| 2026-11-02 | ARKG | Sell | Trimmed | 21,929 | $1.9M |
| 2026-10-30 | ARKG | Sell | Trimmed | 50,859 | $4.4M |
| 2026-10-16 | ARKG | Sell | Trimmed | 59,477 | $3.8M |
| 2026-10-15 | ARKG | Sell | Trimmed | 6,429 | $429K |
| 2026-10-14 | ARKG | Sell | Trimmed | 8,899 | $576K |
| 2026-10-13 | ARKG | Sell | Trimmed | 43,521 | $2.8M |
| 2026-10-12 | ARKG | Sell | Trimmed | 76,589 | $4.8M |
| 2026-10-09 | ARKG | Sell | Trimmed | 57,911 | $3.7M |
CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients;…
See CDNA's full ARK history since 2024, ARK's estimated cost basis, the conviction score and buy/sell alerts.
Open CDNA on FundWake →Data comes from ARK Invest's public daily holdings and trade files. FundWake is not affiliated with ARK Invest. Nothing here is investment advice.